Research Peptide Protocol Library — Canada 2026
Evidence-informed protocols, dosing tables and cycle guides for every peptide we carry. Built for Canadian researchers.
Semaglutide
A GLP-1 receptor agonist that suppresses appetite and slows gastric emptying. The most widely studied injectable weight-management peptide, used weekly at subcutaneous doses.
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.50 mg |
| 9–12 | 1.0 mg |
| 13–16 | 1.7 mg |
| 17+ | 2.4 mg (maintenance) |
Hold each step for 4 weeks. Step up sooner only if GI side effects are mild. Many subjects hold at 1.0–1.7 mg without ever reaching 2.4 mg.
Long-run protocol. Titrate over the first ~16 weeks, then maintain at your effective dose. Stopping commonly leads to weight regain — plan an exit (taper or maintenance dose) before starting.
Key Research Notes
- Inject SC into abdomen, thigh, or upper arm. Rotate sites weekly.
- Nausea, reduced appetite and slower digestion are expected early — dose timing matters; evening injection often reduces daytime symptoms.
- Dose on the same day each week. Missing a dose: take it as soon as you remember within 5 days.
- Reconstitute with bacteriostatic water. A 2 mL fill on a 5 mg vial gives 2.5 mg/mL — 0.25 mg = 0.10 mL draw.
Tirzepatide
A dual GLP-1 and GIP receptor agonist with stronger weight-loss outcomes in trials than GLP-1 mono-agonists. Injected once weekly subcutaneously.
| Weeks | Dose |
|---|---|
| 1–4 | 2.5 mg |
| 5–8 | 5.0 mg |
| 9–12 | 7.5 mg |
| 13–16 | 10 mg |
| 17–20 | 12.5 mg |
| 21+ | 15 mg (max) |
Step up by 2.5 mg every 4 weeks as tolerated. Many subjects find their effective dose at 7.5–10 mg and don’t need to push higher.
Long-run protocol. Titrate over 3–5 months, then hold your maintenance dose. Stopping tends to bring weight back — plan your exit.
Key Research Notes
- With a 30 mg vial, 3 mL of bac water gives 10 mg/mL — clean round numbers at every titration step.
- GI side effects (nausea, reduced appetite) are most pronounced during dose escalation. Eat smaller meals, avoid high-fat foods early on.
- Inject SC into abdomen, thigh, or upper arm — rotate weekly. Same day each week.
- Headache and fatigue are common in the first few weeks as the body adjusts.
Retatrutide
A triple GLP-1, GIP, and glucagon receptor agonist — the most potent fat-loss peptide currently in clinical development. Phase 3 data shows the largest weight-loss numbers of any injectable investigated to date.
| Weeks | Dose |
|---|---|
| 1–4 | 0.5 mg |
| 5–8 | 1.0 mg |
| 9–12 | 2.0 mg |
| 13–16 | 3.0 mg |
| 17–24 | 4–6 mg (titrate to tolerance) |
Step up every 4 weeks as tolerated. GI side effects are stronger than with GLP-1 mono-agonists — go slow.
Run in 4-week blocks while titrating. Full programs run 16–24 weeks or longer. Many taper the dose down at the end rather than stopping cold, since abrupt cessation tends to bring weight back.
Key Research Notes
- Must be reconstituted with plain bacteriostatic water — not saline bac water.
- Inject SC into abdomen, thigh, or upper arm — rotate weekly on the same day each week.
- Triple-agonist activity means GI side effects (nausea, vomiting, diarrhea) can be more pronounced than with sema or tirz — slow titration is essential.
- Glucagon component adds metabolic rate support on top of appetite suppression.
Cagrilintide
A long-acting amylin analogue that slows gastric emptying and promotes satiety independently of the GLP-1 pathway. Often stacked with semaglutide (the CagriSema combination) for additive fat-loss effects.
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.50 mg |
| 9–12 | 1.0 mg |
| 13–16 | 1.7 mg |
| 17+ | 2.4 mg (maintenance) |
Mirrors the semaglutide titration schedule. Hold each step for 4 weeks. When stacking with sema, start both on the same schedule.
Titrate over ~16 weeks, then maintain. Some reduce to 1.8–2.0 mg weekly once at goal to hold results.
Key Research Notes
- Commonly paired with semaglutide (CagriSema) — both injected once weekly, can be done on the same day at separate injection sites.
- Amylin agonism adds satiety signalling beyond what GLP-1 alone provides.
- Inject SC into abdomen, thigh, or upper arm. Rotate sites.
- Reconstitute with bacteriostatic water. 2 mL per 5 mg vial = 2.5 mg/mL.
BPC-157
Body Protection Compound-157 — a 15-amino-acid peptide derived from human gastric juice. One of the most studied healing peptides in research, with evidence across tendon, ligament, muscle, gut and neurological models.
| Application | Daily dose | Frequency |
|---|---|---|
| Minor tendonitis / gut support | 0.20–0.25 mg | Once daily |
| Moderate injury / chronic pain | 0.25–0.50 mg | Once or split AM/PM |
| Severe injury / post-surgical | 0.50–0.75 mg | Split AM/PM |
4–6 weeks for most injuries, up to 8 weeks for severe cases. Daily use, often 5 days on / 2 days off. Take a 4-week break between full cycles.
Key Research Notes
- Inject SC close to the injury site (within 1–2 inches) for local injuries; abdomen for systemic gut/brain applications.
- Anti-inflammatory effect typically noticeable in the first week; structural repair takes 3–8 weeks.
- Safe to exercise during BPC-157 use — many researchers train through it. Avoid alcohol as it may reduce efficacy.
- Reconstitute with bacteriostatic water only. Stable refrigerated for 4–6 weeks after reconstitution.
TB-500
A synthetic fragment of Thymosin Beta-4 with systemic healing and anti-inflammatory effects. Unlike BPC-157, TB-500 does not need to be injected near the injury — it works systemically and circulates throughout the body.
| Phase | Dose | Frequency |
|---|---|---|
| Loading (weeks 1–4) | 2.0–2.5 mg | 2× per week |
| Loading (weeks 5–6) | 2.0 mg | Once weekly |
| Maintenance | 2.0 mg | Once every 2 weeks |
Load for 4–6 weeks, then shift to weekly maintenance. Common overall cycle is 8–12 weeks on, then a break of equal length.
Key Research Notes
- Inject SC into abdomen — no need to be near the injury. TB-500 circulates systemically.
- Often stacked with BPC-157 (see REGEN Blend) for synergistic local + systemic healing.
- Anti-inflammatory effects begin within the first 1–2 weeks; tissue repair takes 4–8 weeks.
- Reconstitute with bacteriostatic water. The 10 mg vial with 2 mL bac water = 5 mg/mL; a 2.0 mg dose = 0.4 mL draw.
TB-500 + BPC-157 Blend
The most popular healing stack in peptide research — BPC-157 provides targeted local repair while TB-500 works systemically. Together they cover complementary pathways for accelerated recovery.
| Phase | Dose (per compound) | Frequency |
|---|---|---|
| Acute injury (weeks 1–4) | 0.25 mg BPC + 2.0 mg TB | Daily or 5 on/2 off |
| Sub-acute (weeks 5–8) | 0.25 mg BPC + 2.0 mg TB | 3–4× weekly |
| Maintenance | 0.25 mg BPC + 2.0 mg TB | 1–2× weekly |
Run a 6–12 week block, then take a break. Acute injuries respond faster (2–3 weeks) than chronic or post-surgical cases (4–8 weeks).
Key Research Notes
- For a blend vial, inject SC into abdomen for systemic effect. Can also inject near the injury for additional local BPC-157 effect.
- BPC-157 upregulates GH receptors in healing tissue; TB-500 promotes actin polymerisation and cell migration — they act on different repair mechanisms.
- Most researchers see the greatest benefit in the first 6–8 weeks; extending past 12 weeks has diminishing returns.
- Reconstitute with bacteriostatic water. Label the vial with the reconstitution date.
GHK-Cu (Copper Peptide)
A naturally occurring copper-binding tripeptide that activates over 4,000 human genes involved in regeneration. Research shows increased collagen synthesis by up to 70%, improved skin firmness and hair follicle stimulation.
| Application | Dose | Frequency |
|---|---|---|
| General anti-aging / skin | 1–2 mg/day | Daily or 5 on/2 off |
| Hair loss / scalp (systemic) | 1–2 mg/day | Daily |
| Wound healing / collagen support | 2 mg/day | Daily |
Run in 30-day blocks, then take a short break (1–2 weeks) before the next round. Skin and hair effects build over 8–12 weeks of consistent use.
Key Research Notes
- Lyophilized GHK-Cu powder has a slight blue/green tint from the copper — this is normal. Reconstituted solution may be faintly blue.
- For topical applications (skin/hair), a topical GHK-Cu serum alongside systemic injection provides complementary surface-level and systemic coverage.
- Inject SC into abdomen; rotate sites.
- Reconstitute with bacteriostatic water. 2 mL per 50 mg vial = 25 mg/mL; 1 mg dose = 0.04 mL (4 units on insulin syringe).
AHK-Cu (Copper Peptide)
A copper-binding tripeptide related to GHK-Cu with a particular affinity for hair follicle stimulation and scalp vascularisation. Studied for androgenetic alopecia and scalp health in research settings.
| Application | Dose | Frequency |
|---|---|---|
| Hair follicle stimulation | 1–2 mg/day | Daily or 5 on/2 off |
| Scalp circulation support | 1–2 mg/day | Daily |
Run 8–12 week blocks; hair-related effects typically require 12–16 weeks of consistent use to be apparent. Take a 4-week break between cycles.
Key Research Notes
- Often stacked with GHK-Cu for broader peptide copper coverage targeting both skin and hair simultaneously.
- Inject SC into abdomen; for local scalp effects, some researchers microdose subcutaneously near the scalp hairline.
- The blue-green tint of copper peptides is normal and does not indicate a problem.
- Reconstitute with bacteriostatic water. Refrigerate and use within 4–6 weeks.
GLOW Blend (GHK-Cu + TB-500 + BPC-157)
A triple-compound healing and anti-aging blend combining GHK-Cu (skin/collagen), TB-500 (systemic repair), and BPC-157 (local tissue repair). Designed for researchers studying compound synergies in recovery and aesthetics.
| Phase | Frequency |
|---|---|
| Loading (weeks 1–2) | Daily injection |
| Maintenance (weeks 3–12) | 5 days on / 2 days off, or 3×/week |
Typical dose per injection is the full reconstituted vial dose based on your concentration. Follow the reconstitution instructions included with each vial.
Run 8–12 weeks, often 5 days on / 2 days off. Take 4–8 weeks off, then reassess. Skin and hair improvements build over 8–12 weeks.
Key Research Notes
- Each compound in GLOW acts through different mechanisms — GHK-Cu activates regeneration genes, TB-500 promotes systemic repair, BPC-157 provides local healing.
- Inject SC into abdomen. No need to inject near a specific injury site — the blend provides systemic coverage.
- The blue-green tint from GHK-Cu in the reconstituted solution is normal.
- Refrigerate after reconstitution. Use within 4–6 weeks.
KLOW Blend (BPC-157 + GHK-Cu + TB-500 + KPV)
A four-compound healing blend adding KPV’s anti-inflammatory and gut-healing properties to the GLOW stack (BPC-157 + GHK-Cu + TB-500). Designed for comprehensive recovery + immune regulation research.
| Phase | Frequency |
|---|---|
| Loading (weeks 1–2) | Daily injection |
| Maintenance (weeks 3–12) | 5 days on / 2 days off, or 3×/week |
Typically 8–12 weeks, 5 on / 2 off, then a 4–8 week break. The addition of KPV makes KLOW particularly suited for research involving inflammatory conditions or gut permeability.
Key Research Notes
- KPV (Lys-Pro-Val) is an anti-inflammatory tripeptide that also promotes gut barrier repair — it adds immune-regulatory properties to the healing stack.
- Each of the four compounds acts via a distinct mechanism, providing multi-pathway coverage.
- Inject SC into abdomen. Rotate sites to prevent injection site reactions.
- Blue tint from GHK-Cu in the solution is normal.
KPV
Lys-Pro-Val — a C-terminal fragment of alpha-MSH with potent anti-inflammatory and gut-healing properties. Studied for inflammatory bowel conditions, skin inflammation and immune modulation in research models.
| Application | Dose | Frequency |
|---|---|---|
| Active flare / gut healing | 0.5 mg | Once daily |
| Skin inflammation | 0.2–0.5 mg | Once daily |
| General immune support | 0.2–0.3 mg | Once daily |
Typically a 2–4 week course, then a break. Repeat as needed around flares. KPV works best during active inflammatory periods rather than as a continuous supplement.
Key Research Notes
- Community dosing data for KPV is less settled than for other peptides — 0.5 mg/day is the most commonly reported working dose.
- Inject SC into abdomen. For gut applications, oral peptide research is also ongoing, but SC is the standard research route.
- Well tolerated in most research reports. No significant adverse effects at standard doses.
- Reconstitute with bacteriostatic water. A 10 mg vial with 2 mL bac water = 5 mg/mL.
Tesamorelin
A stabilized GHRH analogue with the strongest clinical data of any peptide in the GH-axis class. FDA/Health Canada approved as Egrifta for HIV-associated lipodystrophy, with Phase 3 data showing 15.2% visceral fat reduction.
| Application | Dose | Frequency |
|---|---|---|
| Visceral fat reduction | 1–2 mg/day | Daily, before bed |
| GH axis support | 1 mg/day | Daily, before bed |
Inject fasted, 2 hours after the last meal. Tesamorelin stimulates a natural GH pulse from the pituitary rather than supplying exogenous GH.
Run for at least 3 months — visceral fat reduction is gradual and builds over the cycle. Many continue longer while tracking results. Does not suppress endogenous GH production.
Key Research Notes
- Require a 2-hour fast before injection for optimal GH pulse — carbohydrates and fats blunt the GH response.
- Preserves the pituitary’s natural feedback loop, unlike exogenous HGH which bypasses it entirely.
- Visceral fat (intra-abdominal) is the primary target; subcutaneous fat is less affected.
- 15.2% VAT reduction at 2 mg/day seen in controlled trials — effects are greatest in subjects with elevated visceral fat.
Sermorelin
The shortest active fragment of GHRH that retains full biological activity. FDA-approved as Geref until 2008 (withdrawn for commercial, not safety, reasons). The most studied GHRH peptide in anti-aging research contexts.
| Protocol | Dose | Frequency |
|---|---|---|
| Entry-level / anti-aging | 0.10–0.20 mg | Nightly, fasted |
| Standard research | 0.20–0.30 mg | Nightly or 5 on/2 off |
Inject 30–60 minutes before sleep. A 1–2 hour fast before injection maximizes the GH pulse.
Run 8–12 weeks, often 5 on / 2 off, then take a break. Preserves pituitary function — does not suppress natural GH production.
Key Research Notes
- Sermorelin’s half-life is ~10–20 minutes — it triggers a natural GH pulse and is then cleared. This is why bedtime dosing is ideal (aligns with natural sleep-phase GH release).
- Unlike exogenous HGH, sermorelin works through the pituitary and maintains the natural GH feedback loop.
- Headaches and flushing can occur; typically mild and resolve as the body adjusts.
- Often stacked with Ipamorelin for synergistic GHRH + GHRP action.
Ipamorelin
A selective pentapeptide GHRP that stimulates GH release without the cortisol elevation, prolactin increase, or significant hunger stimulation seen with other GHRPs. The cleanest GH secretagogue profile for daily bedtime protocols.
| Protocol | Dose | Timing | Frequency |
|---|---|---|---|
| Entry level | 0.10 mg | 30 min before bed | Daily |
| Standard | 0.20–0.30 mg | 30 min before bed | Daily or 5 on/2 off |
| Split dose | 0.15 mg AM + 0.15 mg PM | AM (fasted) + bedtime | Daily |
Run 8–12 weeks (5 on / 2 off), then a break. Half-life ~2 hours — produces clean, brief GH pulses at the time of injection.
Key Research Notes
- No significant cortisol or prolactin rise at standard doses — the key advantage over GHRP-2 and GHRP-6.
- Minimal hunger stimulation compared to GHRP-6; evening dosing before sleep minimises any impact on daytime eating.
- Frequently stacked with CJC-1295 (No DAC) or Sermorelin for synergistic GHRP + GHRH action.
- Reconstitute with bacteriostatic water. A 5 mg vial with 2 mL bac water = 2.5 mg/mL; 0.20 mg = 0.08 mL draw.
CJC-1295 (No DAC)
A modified GHRH peptide (also called Mod GRF 1-29) that stimulates pulsatile GH release. The No DAC version has a 30-minute half-life — ideal for timed pre-sleep GH pulses when stacked with Ipamorelin.
| Protocol | Dose | Timing |
|---|---|---|
| Solo use | 0.10 mg | 30 min before bed, fasted |
| Stacked with Ipamorelin | 0.10 mg CJC + 0.20–0.30 mg Ipa | Together, 30 min before bed |
Run 8–12 weeks, 5 on / 2 off, then a break. When stacked with Ipamorelin, they synergistically amplify each other’s GH-releasing effect.
Key Research Notes
- CJC-1295 No DAC (Mod GRF 1-29) has a ~30-min half-life — unlike the DAC version which lasts days. This is intentional: it mimics the natural GHRH pulse pattern.
- Must be injected fasted for optimal GH release — carbs and fats blunt the GH response.
- When stacked with Ipamorelin, inject both simultaneously in the same syringe or sequentially in the same sitting.
- Reconstitute with bacteriostatic water. Standard: 1–2 mL per vial.
CJC-1295 / Ipamorelin Blend
The most popular GH axis stack in peptide research — CJC-1295 (GHRH) and Ipamorelin (GHRP) work through complementary receptors to produce a synergistic GH pulse significantly larger than either compound alone.
| Protocol | Timing | Frequency |
|---|---|---|
| Standard (body composition) | 30 min before bed, fasted | Daily |
| Advanced (AM + PM) | AM fasted + PM before bed | Daily (2 injections) |
Typical dose per injection: 0.10 mg CJC + 0.20–0.30 mg Ipamorelin. With a 10 mg blend vial (1:1 split = 5 mg each), reconstitute with 2 mL bac water = 2.5 mg/mL per compound.
Run 8–12 weeks (extend to 16 if desired), 5 on / 2 off, then a break. Effects on body composition build gradually over 8–12 weeks.
Key Research Notes
- The two compounds work on different receptors (GHRH receptor vs. ghrelin receptor) — stacking them produces a GH pulse 4–10× the amplitude of either alone.
- Both compounds must be injected fasted — even small amounts of food (especially carbs/fat) will blunt the GH response.
- Ipamorelin does not raise cortisol or prolactin, making this stack cleaner than CJC with GHRP-2 or GHRP-6.
- Expected benefits build over 8–12 weeks: improved sleep quality, body composition changes, joint/recovery support.
Melanotan II
A synthetic melanocortin receptor agonist that stimulates melanin production for UV-activated skin tanning and has documented effects on sexual arousal. Requires UV light exposure to produce visible tanning.
| Phase | Dose | Frequency |
|---|---|---|
| Loading (days 1–10) | 0.25 mg | Daily |
| Maintenance | 0.5–1.0 mg | 1–2× per week |
UV exposure (natural or tanning bed) is required for visible melanin activation. The peptide primes the melanocytes; UV triggers the actual melanin production.
Loading phase 1–2 weeks of small daily doses, then occasional maintenance doses to maintain the tan. Many cycle off after the initial load and use single top-up doses before UV exposure.
Key Research Notes
- Nausea and flushing are common in the first 1–2 hours after injection, especially at higher doses — start at 0.25 mg.
- Sexual effects (erections in male subjects; arousal in female subjects) are a primary pharmacological effect, not a side effect. This is the basis for PT-141 (a related compound).
- Do not inject immediately before UV exposure — inject in the evening and expose the next day for best results.
- Reconstitute with bacteriostatic water. Common approach: 1 mL bac water per 10 mg vial = 10 mg/mL; 0.25 mg dose = 0.025 mL (2.5 units on an insulin syringe).
PT-141 (Bremelanotide)
A melanocortin receptor agonist developed from Melanotan II that was optimised for sexual arousal and approved as Vyleesi (bremelanotide) for HSDD in women. In research use, injected on-demand before sexual activity.
| Experience | Dose | Timing |
|---|---|---|
| First use / sensitive | 0.5–0.75 mg | 45–60 min before activity |
| Standard dose | 1.0–1.75 mg | 45–60 min before activity |
| Maximum | 2.0 mg | 45–60 min before activity |
Used occasionally, on demand, rather than in a continuous daily cycle. Not recommended more than once per day.
Key Research Notes
- Nausea is the most common side effect, particularly at higher doses and in first-time users — start conservatively at 0.5–0.75 mg.
- Flushing, headache, and blood pressure changes can occur in the 1–2 hours after injection.
- Unlike phosphodiesterase inhibitors (e.g. sildenafil), PT-141 acts centrally on arousal and desire rather than peripherally on blood flow.
- Does not cause tanning at single on-demand doses. Melanotan II at repeated loading doses is required for tanning effects.
Kisspeptin-10
A neuropeptide that acts upstream on the hypothalamic-pituitary-gonadal (HPG) axis to stimulate GnRH and downstream LH secretion. Studied for endogenous testosterone and gonadotropin support.
| Protocol | Dose | Frequency |
|---|---|---|
| HPG axis support | 0.1 mg/kg (typical 5–10 mg) | 2–3× weekly |
| LH pulse study | 5 mg | Once or twice weekly |
Typically used in shorter cycles rather than continuously. Protocols are less settled than for GLP-1 drugs; the HPG axis responds gradually.
Key Research Notes
- Acts upstream on the hormone axis — stimulates LH and downstream testosterone through natural pituitary pathways.
- Inject subcutaneously; rotate sites.
- Community protocols for kisspeptin-10 are still evolving. The dosing above reflects common reported ranges.
- Generally well tolerated in studies. Transient LH surges have been documented within hours of injection.
5-Amino-1MQ
A small-molecule NNMT (Nicotinamide N-Methyltransferase) inhibitor that upregulates NAD+ biosynthesis and shifts cells toward fat-burning metabolism. Studied for obesity and metabolic syndrome models.
| Protocol | Dose | Frequency |
|---|---|---|
| Entry dose | 10 mg | Daily |
| Standard dose | 50 mg | Daily |
Inject subcutaneously. Works best during a caloric deficit or active cutting phase. Many researchers note synergy with NAD+ supplementation.
Run in 4–8 week blocks, ideally during a cutting or caloric-deficit phase. Effects build over the cycle as NNMT inhibition shifts cellular metabolism.
Key Research Notes
- NNMT inhibition leads to higher cellular NAD+ levels, increasing mitochondrial activity and fat oxidation.
- Works best in a caloric deficit — it amplifies metabolic rate changes rather than being a standalone fat-loss agent.
- Some researchers stack with NAD+ injections for a combined NAD+ biosynthesis approach.
- Reconstitute with bacteriostatic water.
MOTS-c
A mitochondria-derived peptide encoded by the mitochondrial genome. Research shows it improves insulin sensitivity, promotes fat utilisation, and has exercise-mimetic effects. Levels decline significantly with age.
| Protocol | Dose | Frequency |
|---|---|---|
| Metabolic support | 5–10 mg | 2–3× weekly |
| Longevity / anti-aging | 5–10 mg | Weekly |
Run 4–8 week blocks, then a break of similar length. Effects build over the cycle rather than from any single dose — mitochondrial adaptation takes time.
Key Research Notes
- MOTS-c is naturally produced in the mitochondria and declines with age — exogenous administration is studied as a way to restore youthful mitochondrial signalling.
- Exercise significantly amplifies MOTS-c’s effects; research subjects who train alongside MOTS-c see enhanced metabolic improvements.
- Inject SC into abdomen. IV administration has been used in studies but SC is the common research route.
- Reconstitute with bacteriostatic water. Stable refrigerated for 4–6 weeks after reconstitution.
NAD+
Nicotinamide Adenine Dinucleotide — a coenzyme found in every cell, critical for ATP production, DNA repair, and sirtuin pathway activation. NAD+ levels decline sharply with age. Injectable NAD+ bypasses oral absorption limitations.
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| Loading (initial) | 250–500 mg | Daily for 4–5 days | 1 week |
| Maintenance | 100–250 mg | 3× weekly | Ongoing |
SC injection is well tolerated. IV administration delivers faster, but SC is the practical standard for regular self-research protocols.
Run three times weekly in blocks of 4–6 weeks, then assess. Many researchers do a quarterly loading week followed by maintenance protocols year-round.
Key Research Notes
- NAD+ levels decline ~50% by age 50. IV NAD+ therapy is offered clinically; injectable SC provides a practical research alternative.
- A burning sensation at the injection site during administration is common — inject slowly over 30–60 seconds.
- Often stacked with MOTS-c or Epitalon for combined longevity protocols.
- Reconstitute with bacteriostatic water. Use promptly — NAD+ degrades faster than most peptides once reconstituted. Refrigerate and use within 2–4 weeks.
Semax
A synthetic ACTH(4-10) analogue developed in Russia with nootropic and neuroprotective properties. Research shows upregulation of BDNF (brain-derived neurotrophic factor), improved focus, memory and stress resilience.
| Protocol | Dose | Timing |
|---|---|---|
| Cognitive performance | 0.3–0.6 mg/day | AM, or split AM + midday |
| Neuroprotective | 0.3–0.5 mg/day | AM (fasted) |
Short courses of 5–10 days during demanding cognitive periods, then a break. Dose earlier in the day — avoid evening use as it can disrupt sleep.
Key Research Notes
- Dose in the morning or early afternoon only. Evening dosing commonly disrupts sleep.
- Nootropic effects are typically noticeable within the first few days of a course — sharp focus, improved recall.
- Often stacked with Selank (Semax for focus; Selank for calm) to balance stimulation with anxiety reduction.
- Generally well tolerated. Some researchers report mild agitation at higher doses — reduce if this occurs.
Selank
A synthetic analogue of tuftsin with anxiolytic and nootropic effects. Research shows GABA pathway modulation for reduced anxiety and stress without sedation, and immune-modulatory properties.
| Protocol | Dose | Frequency |
|---|---|---|
| Anxiety / stress reduction | 0.2–0.4 mg/day | Once daily |
| Stacked with Semax | 0.2 mg Selank + 0.3 mg Semax | Once daily (AM) |
Short courses of 1–2 weeks during stressful periods, then a break. Unlike benzodiazepines, selank does not cause dependence or withdrawal.
Key Research Notes
- A calming, anti-anxiety nootropic — pairs well with Semax for a focus-plus-calm combination (Semax provides activation, Selank prevents over-stimulation).
- No sedation at standard doses; unlike benzodiazepines, does not impair cognitive function.
- Used in short courses rather than indefinitely — the anxiolytic effect is best deployed during high-stress research or demanding periods.
- Generally well tolerated. No significant adverse effects reported at standard doses.
Pinealon
A peptide bioregulator (Glu-Asp-Arg) developed in Russia targeting pineal gland and brain cells. Studied for cognitive support, memory, circadian rhythm regulation and neuroprotective effects in aging models.
| Protocol | Dose | Frequency |
|---|---|---|
| Brain / cognition support | 1.0–1.5 mg/day | Daily for 10–20 days |
Short courses of 10–20 days, then a break. Repeat 1–2× per year, or seasonally. Peptide bioregulators like Pinealon work best in defined courses rather than continuous daily use.
Key Research Notes
- Developed alongside Epithalon, Vilon and other Russian peptide bioregulators as part of the Khavinson peptide research programme.
- Evening dosing may support circadian rhythm regulation and improve sleep quality.
- Works best in defined 10–20 day courses — long-term continuous use is not the standard approach.
- Generally well tolerated. Reconstitute with bacteriostatic water.
Epitalon (Epithalamin)
A tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland, studied for telomerase activation, anti-aging effects, and circadian rhythm normalisation. One of the most extensively researched Russian peptide bioregulators.
| Protocol | Dose | Frequency |
|---|---|---|
| Anti-aging / longevity | 5–10 mg/day | Daily |
A 10–20 day daily course, repeated only 1–2 times per year. This is how Epitalon has been studied in longevity research — not as a daily year-round compound.
Key Research Notes
- Telomerase activation — Epitalon is studied for its ability to lengthen telomeres, which shorten with age and are associated with cellular senescence.
- The standard research approach is a 10–20 day intensive course 1-2× per year, not daily continuous use.
- Evening dosing is common as it aligns with the pineal gland’s natural activity cycle.
- Generally well tolerated in reported research. Reconstitute with bacteriostatic water; stable refrigerated for 4–6 weeks.
SS-31 (Elamipretide)
A mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane to protect cardiolipin and restore mitochondrial function. The pharmaceutical version (Elamipretide/Forzinity) received FDA approval for a rare mitochondrial disease in 2025.
| Protocol | Dose | Frequency |
|---|---|---|
| Mitochondrial support | 5–10 mg | 2–3× weekly |
| Daily dosing | 5 mg | Daily |
Run in 4–6 week blocks. SS-31 targets the mitochondria, so it is studied for cdcellular energy, recovery and aging rather than for a quick visible effect — allow time for cumulative benefits.
Key Research Notes
- Can cause a welt at the injection site. Using bacteriostatic water containing 0.9% sodium chloride (saline bac water) instead of plain bac water reduces the injection-site reaction for some researchers.
- A 50 mg vial with 3 mL bac water = 16.7 mg/mL; 5 mg dose = 0.30 mL draw.
- Effects are internal and cumulative — mitochondrial improvements build over weeks rather than being felt as an acute effect.
- The pharmaceutical version (Forzinity/Elamipretide) was FDA-approved in 2025 for Barth syndrome — at doses higher than those used in research contexts.
Thymalin
A thymic peptide bioregulator isolated from calf thymus gland. Studied for immune system modulation and longevity through restoration of T-cell function and normalisation of age-related immune decline (immunosenescence).
| Protocol | Dose | Frequency |
|---|---|---|
| Immune support course | 5–10 mg/day | Daily for 10 days |
Inject SC once daily for a 10-day course. Most researchers run this 1–2 times per year, often in the spring and fall.
A 10-day intensive course, 1–2 times per year. This mirrors the clinical protocols from the Khavinson Russian research programme where Thymalin has the most extensive data.
Key Research Notes
- Part of the Khavinson peptide bioregulator system — studied in extensive Russian clinical research for immune restoration in aging.
- Often paired with Epitalon in longevity stacks: Epitalon for telomere/pineal support + Thymalin for thymic/immune restoration.
- The 10-day course protocol is derived from the original research design — do not use continuously.
- Reconstitute with bacteriostatic water. Refrigerate and use within 4–6 weeks after reconstitution.
Order Research Peptides in Canada — Same-Week Shipping
All Anglo Peptides compounds are third-party HPLC tested for purity ≥94%. COAs available on every batch. Ships across Canada via Canada Post.
Shop All Peptides Questions? Contact Us